NCT05332054

Long-Term Follow-up Study

An Observational Long-Term Follow-up Study of Patients Who Received Prior Caribou Cell Therapy

• Status: Enrolling By Invitation
• Phase: —
• Study type: Observational
• Enrollment: 150 (estimated)
• Sponsor: Caribou Biosciences, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an observational, non-interventional, LTFS of investigational Caribou therapies in patients who have participated in a parent study: a prior Caribou-sponsored clinical study, special access program, or an IIT. The objective is to evaluate the long-term safety, through 15 years post infusion, in patients who received IPs in a Caribou-sponsored clinical study, special access program or IIT.

Detailed description

This is an observational, non-interventional, LTFS of investigational Caribou therapies in patients who have participated in a parent study: a prior Caribou-sponsored clinical study, special access program, or an IIT. The objective is to evaluate the long-term safety, through 15 years post infusion, in patients who received IPs in a Caribou-sponsored clinical study, special access program or IIT.

Conditions

• Lymphoma, Non-Hodgkin
• Relapsed Non-Hodgkin Lymphoma
• Refractory B-Cell Non-Hodgkin Lymphoma
• Non-Hodgkin Lymphoma
• Lymphoma
• B Cell Lymphoma
• B-Cell Non-Hodgkin's Lymphoma
• Hematologic Malignancy
• Relapsed/Refractory Multiple Myeloma
• Relapsed/Refractory Acute Myeloid Leukemia

Interventions

Type	Name	Description
BIOLOGICAL	Caribou-sponsored investigational therapy	N/A this is an observational study

Timeline

• Start date: 2022-03-16
• Primary completion: 2041-12-01
• Completion: 2041-12-01
• First posted: 2022-04-18
• Last updated: 2026-03-12

Locations

31 sites across 1 country: United States

Regulatory

• FDA-regulated drug study